
MDNN: Transgender Mental Health, Opioid Addiction, and Type 1 Diabetes in Food Swamps
Hi, I’m Kevin Kunzmann, I’m Jenna Payesko, and this is MD Magazine News Network - it’s clinical news for connected physicians.
[Kevin]:
[Jenna]: Hey look, bad opioid news. Researchers from the David Geffen School of Medicine at the University of California
[Kevin]: Wow. Bummer.
[Jenna]: Wack indeed. And now for our weekly segment FDA Roundup, let’s go to Matt Hoffman, who’s just going to ramble off some new approvals and maybe let us know how his week was. Go ahead Matt.
[Matt]: The FDA announced TransMedics’s pre-market approval application for the Organ Care System Lung platform for the standard double lung transplant indication, finalized 2 documented recommendation policies they anticipate will drive the development of novel DNA-scanning technology to improve genetic disease diagnosis and treatment guidance, approved the abbreviated new drug application of daptomycin for injection as an antibiotic and generic alternative to Cubicin, accepted a New Drug Application for Alkermes once-daily, oral, investigative major depressive disorder therapy, ALKS 5461, approved Praxbind for the reversal of an anticoagulant in patients in need of emergency procedure, granted Breakthrough Therapy Designation to Hemlibra for patients with hemophilia A without factor 8 inhibitors, and approved Crysvita as the first treatment for XLH in adults and children ages 1 week and older.
Oh and my week was good. I got a haircut. Back to you guys.
[Kevin]: For these stories and more, visit us at mdmag.com. I’m Kevin Kunzmann, and I’m Jenna Payesko. Thank for you watching MDNN.
Related to this article



